Replies to post #310059 on Avid Bioservices Inc (CDMO)

[vinmantoo]

Are you ignoring AACR 2017 Abstract/Poster # 1651 of MSKCC/PPHM? Your statement appears far too broad, IMO. MSKCC/Ludwig did the work reflected on that poster.

Why do you keep bringing up pre-clinical data when what matters is clinical trial data? That is where Bavi's record is perfect, a perfect failure.

KITE had 1 or 2 deaths in its trials also, did it not? Not as bad as JUNO...those cytokine storms can wreak havoc at inappropriate times.

Yet somehow GILD bought KITE at a nice premium and NOBODY wants to partner with, let alone buy PPHM. It makes you think, doesn't it? Well, it should make you think.

What should also make you think are the vague comments PPHM makes about exosomes and the even vaguer comments about their antibody target platform.